TRK fusion cancer: updated analysis for Larotrectinib has confirmed high response rate and durable responses over three years in children and adults
Updated clinical data for Larotrectinib ( Vitrakvi ) in adult and pediatric patients with TRK fusion cancer showed a high response rate with an overall response rate ( ORR ) of 79% ( 95% CI: 72–85 ) w ...
read article